Neogenomics (NEO) Assets (2010 - 2026)

Neogenomics (NEO) has reported Assets for 17 consecutive years, with $1.4 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Assets fell 2.99% year-over-year to $1.4 billion; the trailing twelve-month figure through Jun 2026 stood at $1.4 billion (down 2.99% YoY), and the FY2025 full-year result was $1.4 billion, down 16.98% from the prior year.
• Assets steadied at $1.4 billion in Q2 2026 per NEO's latest filing, from $1.3 billion in the prior quarter.
• Across five years, Assets topped out at $1.8 billion in Q1 2022 and bottomed at $1.3 billion in Q1 2026.
• Historically, Assets has averaged $1.6 billion across 5 years, with a median of $1.6 billion in 2024.
• The sharpest annual moves came in 2022 and 2025: Assets grew 22.43% in 2022, then declined 16.98% in 2025.
• Over 5 years, Assets stood at $1.7 billion in 2022, then declined by 3.38% to $1.7 billion in 2023, then retreated by 2.57% to $1.6 billion in 2024, then slipped by 16.98% to $1.4 billion in 2025, then decreased by 0.56% to $1.4 billion in 2026.
• According to Business Quant data, Assets over the past three periods registered $1.4 billion, $1.3 billion, and $1.4 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.